---
title: Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma
nct_id: NCT07346404
overall_status: NOT_YET_RECRUITING
phase: PHASE2
sponsor: Assistance Publique - Hôpitaux de Paris
study_type: INTERVENTIONAL
primary_condition: Renal Cell Carcinoma
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07346404.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07346404"
ct_last_update_post_date: 2026-01-16
last_seen_at: "2026-05-12T07:28:42.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma

**NCT ID:** [NCT07346404](https://clinicaltrials.gov/study/NCT07346404)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Assistance Publique - Hôpitaux de Paris
- **Collaborators:** Naogen Pharma
- **Conditions:** Renal Cell Carcinoma
- **Start Date:** 2026-01-01
- **Completion Date:** 2028-01-01
- **CT.gov Last Update:** 2026-01-16

## Brief Summary

This is a pilot prospective longitudinal monocentric, non-comparative, nonrandomised, and non-controlled open study.

is to test whether the intensity of 82-Rb uptake on PET acquisitions is associated to the aggressiveness of RCC on histology (ISUP grades), i.e., to successfully identify high-grade (ISUP grades 3 and 4) vs. lowgrade (ISUP grades 1 and 2) RCC.

## Detailed Description

Tumoral vascularization is an important prognostic marker in renal cell carcinomas (RCC). The evaluation of RCC is often complex before surgery as only a small peripheral segment of the tumor is obtained with biopsy and tend to underestimate the aggressiveness and grade of RCC. Accurate noninvasive evaluation of the aggressiveness of RCC could improve the characterization of tumors before surgery and help guide patient management. Radiolabeled water has demonstrated its interest for the quantification of the vascularization of renal tumors in Positron Emission Tomography (PET). The synthesis of radiolabeled water requires, however, an on-site cyclotron, which is available only in a limited number of hospitals. 82-Rb, a potassium analog and positron-emitting radiotracer, is taken up by myocardial and renal cells. 82-Rb has been used for more than 15 years in North America for the quantification of myocardial perfusion with PET. The solution of 82-Rb chloride is obtained from 82-Sr / 82-Rb radiopharmaceutical generators which have recently obtained a marketing authorization in Europe. These generators can be installed in nuclear medicine departments in hospitals. Myocardial perfusion flow can be precisely quantified by modelling tissue uptake of the tracer on dynamic acquisitions obtained during the intravenous administration of 82-Rb chloride. Our hypothesis is that 82-Rb uptake profile could help grade noninvasively the aggressiveness of renal tumors.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 90 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age ≥ 18 years old
* Signed written informed consent
* French Social Security affiliation
* Patients with high suspicion of or confirmed RCC requiring surgical resection
* Kidney tumor diameter between 2 cm and 7 cm with clear cell imaging feature (hyper vascular lesion with contrast-enhancement similar to the renal cortex on CTA)
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion Criteria:

* Pregnant or breastfeeding women
* Patient under legal protection (guardianship)
* Contraindication to the PET-CT
* Contraindication to the injection of 82-Rb
* Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable
* Patient on SMA (state medical aid)
* Unilateral renal agenesis
* Multicystic renal dysplasia
* Hereditary forms of RCC as VHL, MET, FH and FLCN
* Bosniak 3 cysts
* Hypovascular lesions with enhancement inferior to the renal cortex in corticomedullary-phase images on CTA
* Exclusion of clear renal cell adenocarcinoma on biopsy
* Kidney tumors with high suspicion of extra-renal extension (cT3b, cT3c, cN+ or M+).
```

## Arms

- **82-Rubidium** (OTHER) — 82-Rb; 10 MBq/kg intravenous injection over 30-60 seconds using an automated injection; two injections (Minimal injected activity per injection: 740 MBq ; maximal injected activity per injection: 1480 MBq).

## Interventions

- **82-Rb injection** (DRUG) — Injection of 82-Rb for 82-Rb PET imaging

## Primary Outcomes

- **Classify the aggressiveness of RCC into low grade and high grade based on the 82-Rb uptake intensity in renal tumors on PET.** _(time frame: Up to three months after surgery)_ — Intensity of 82-Rb uptake in the tumor is calculated as the tumor to background ratio (ratio between SUV max in the tumor and the mean SUV in normal renal parenchyma).

High grades are tumors classified as ISUP 3 and 4 on pathology and low grades tumors classified as ISUP 1 and 2 on pathology.

## Secondary Outcomes

- **Correlation between the renal perfusion flow and the degree of neoangiogenesis in the tumor.** _(time frame: Up to three months after surgery)_
- **Association between imaging biomarkers on 82-Rb-PET and the histological type of the tumor.** _(time frame: Up to three months after surgery)_
- **Association between imaging biomarkers on 82-Rb-PET and tumor aggressiveness (ISUP grades) in patients with clear-cell renal adenocarcinomas.** _(time frame: Up to three months after surgery)_
- **Correlation between 82-Rb uptake and the degree of neoangiogenesis in the tumor.** _(time frame: Up to three months after surgery)_
- **Correlation between the estimated residual renal function and the observed renal function change.** _(time frame: Up to three months after surgery)_
- **To compare the diagnostic performance of biopsy and 82-Rb-PET for the ISUP grading of clear cell renal adenocarcinomas against the final results of histology (gold standard) of the renal tumor.** _(time frame: Up to three months after surgery)_
- **Safety and tolerance of 82-Rb** _(time frame: Up to 72 hours after the PET with injection of the radiopharmaceutical)_

## Locations (2)

- AP-HP - hôpital européen Georges-Pompidou, Paris, France
- AP-HP - hôpital européen Georges-Pompidou, Paris, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.ap-hp - hôpital européen georges-pompidou|paris||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07346404.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07346404*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*